Eli Lilly And Co LLY has achieved a year-to-date (YTD) increase of 32.11% as of Friday, according to Benzinga Pro. This surge has had varied effects on several ETFs that hold significant stakes in the pharmaceutical giant. Several ETFs with substantial holdings in Eli Lilly have experienced varied performances during the same period.
What Happened: The iShares U.S. Pharmaceuticals ETF IHE with a 20.33% allocation to Eli Lilly, reported a YTD gain of 10.89%. Meanwhile, the Roundhill GLP-1 & Weight Loss ETF OZEM, holding 15.86% in Eli Lilly, saw a modest YTD increase of 3.74%.
See Also: Candel Therapeutics Stock Surges Over 100%
Conversely, the Horizon Kinetics Medical ETF MEDX, with Eli Lilly making up 16.06% of its portfolio, experienced a YTD decline of 1.56%. Similarly, the Amplify Weight Loss Drug & Treatment ETF THNR, with a 14.43% exposure to Eli Lilly, also saw its YTD returns decrease by 6.27%.
Lastly, the iShares U.S. Healthcare ETF IYH, which includes an 11.76% stake in Eli Lilly, recorded a YTD increase of 2.68%.
Buying $1000 In LLY vs. ETFs: If an investor had bought $1000 of LLY stock earlier this year, it would be worth $1,251 today based on a price of $782.35 for Eli Lilly at the time of writing. At the same time, IHE would have been worth $1100 based on a price of $67.11 for iShares US Pharmaceuticals ETF at the time of writing.
Why It Matters: Recently, the company announced a massive $15 billion share buyback plan and a 15% dividend increase. These strategic moves come as the company enjoys the success of its blockbuster drugs, Mounjaro and Zepbound, despite facing mixed technical signals on the charts.
Moreover, Eli Lilly has been heavily investing in its production capabilities. The company recently announced a $3 billion expansion of its manufacturing facility in Kenosha County, Wisconsin. This expansion is part of a broader $23 billion investment to meet the growing demand for diabetes, obesity, and pipeline medicines, further solidifying its position in the pharmaceutical industry.
Read Next:
Disclaimer: This content was partially produced with the help of Benzinga Neuro and was reviewed and published by Benzinga editors.
Image via Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
